Amdocs (DOX) Competitors

Accenture has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Amdocs has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Accenture has higher revenue and earnings than Amdocs. Accenture is trading at a lower price-to-earnings ratio than Amdocs, indicating that it is currently the more affordable of the two stocks.

Accenture currently has a consensus target price of $195.00, indicating a potential upside of 56.10%. Amdocs has a consensus target price of $86.67, indicating a potential upside of 68.45%. Given Amdocs' higher probable upside, analysts clearly believe Amdocs is more favorable than Accenture.

Accenture pays an annual dividend of $6.52 per share and has a dividend yield of 5.2%. Amdocs pays an annual dividend of $2.28 per share and has a dividend yield of 4.4%. Accenture pays out 52.1% of its earnings in the form of a dividend. Amdocs pays out 45.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Accenture has increased its dividend for 20 consecutive years and Amdocs has increased its dividend for 14 consecutive years. Accenture is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

75.1% of Accenture shares are held by institutional investors. Comparatively, 92.0% of Amdocs shares are held by institutional investors. 0.0% of Accenture shares are held by company insiders. Comparatively, 15.4% of Amdocs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amdocs has a net margin of 11.81% compared to Accenture's net margin of 10.66%. Accenture's return on equity of 26.47% beat Amdocs' return on equity.

In the previous week, Accenture had 44 more articles in the media than Amdocs. MarketBeat recorded 50 mentions for Accenture and 6 mentions for Amdocs. Amdocs' average media sentiment score of 0.74 beat Accenture's score of 0.48 indicating that Amdocs is being referred to more favorably in the news media.

Amdocs has a net margin of 11.81% compared to Leidos' net margin of 8.15%. Leidos' return on equity of 31.92% beat Amdocs' return on equity.

Leidos has higher revenue and earnings than Amdocs. Leidos is trading at a lower price-to-earnings ratio than Amdocs, indicating that it is currently the more affordable of the two stocks.

Amdocs pays an annual dividend of $2.28 per share and has a dividend yield of 4.4%. Leidos pays an annual dividend of $1.72 per share and has a dividend yield of 1.7%. Amdocs pays out 45.6% of its earnings in the form of a dividend. Leidos pays out 15.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amdocs has raised its dividend for 14 consecutive years and Leidos has raised its dividend for 6 consecutive years. Amdocs is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Leidos had 8 more articles in the media than Amdocs. MarketBeat recorded 14 mentions for Leidos and 6 mentions for Amdocs. Amdocs' average media sentiment score of 0.74 beat Leidos' score of 0.70 indicating that Amdocs is being referred to more favorably in the media.

Amdocs presently has a consensus target price of $86.67, indicating a potential upside of 68.45%. Leidos has a consensus target price of $177.92, indicating a potential upside of 77.11%. Given Leidos' stronger consensus rating and higher probable upside, analysts plainly believe Leidos is more favorable than Amdocs.

92.0% of Amdocs shares are held by institutional investors. Comparatively, 76.1% of Leidos shares are held by institutional investors. 15.4% of Amdocs shares are held by insiders. Comparatively, 0.8% of Leidos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Amdocs has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Leidos has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Amdocs has higher earnings, but lower revenue than CACI International. Amdocs is trading at a lower price-to-earnings ratio than CACI International, indicating that it is currently the more affordable of the two stocks.

Amdocs has a net margin of 11.81% compared to CACI International's net margin of 5.86%. Amdocs' return on equity of 19.77% beat CACI International's return on equity.

In the previous week, Amdocs had 2 more articles in the media than CACI International. MarketBeat recorded 6 mentions for Amdocs and 4 mentions for CACI International. Amdocs' average media sentiment score of 0.74 beat CACI International's score of 0.69 indicating that Amdocs is being referred to more favorably in the media.

Amdocs presently has a consensus price target of $86.67, indicating a potential upside of 68.45%. CACI International has a consensus price target of $622.82, indicating a potential upside of 36.27%. Given Amdocs' higher possible upside, equities analysts clearly believe Amdocs is more favorable than CACI International.

Amdocs has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, CACI International has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

92.0% of Amdocs shares are held by institutional investors. Comparatively, 86.4% of CACI International shares are held by institutional investors. 15.4% of Amdocs shares are held by insiders. Comparatively, 1.1% of CACI International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Amdocs had 2 more articles in the media than Gartner. MarketBeat recorded 6 mentions for Amdocs and 4 mentions for Gartner. Amdocs' average media sentiment score of 0.74 beat Gartner's score of 0.39 indicating that Amdocs is being referred to more favorably in the media.

Amdocs has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Gartner has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Gartner has higher revenue and earnings than Amdocs. Amdocs is trading at a lower price-to-earnings ratio than Gartner, indicating that it is currently the more affordable of the two stocks.

92.0% of Amdocs shares are held by institutional investors. Comparatively, 91.5% of Gartner shares are held by institutional investors. 15.4% of Amdocs shares are held by insiders. Comparatively, 2.6% of Gartner shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amdocs currently has a consensus price target of $86.67, indicating a potential upside of 68.45%. Gartner has a consensus price target of $174.10, indicating a potential upside of 30.72%. Given Amdocs' stronger consensus rating and higher possible upside, equities research analysts plainly believe Amdocs is more favorable than Gartner.

Amdocs has a net margin of 11.81% compared to Gartner's net margin of 11.44%. Gartner's return on equity of 161.39% beat Amdocs' return on equity.